SCHEDULE: Invus Group Discloses Stake in Tenax Therapeutics

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 2.1% of Tenax Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Invus Public Equities, L.P. and its affiliates, including Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Raymond Debbane, have disclosed their beneficial ownership of Tenax Therapeutics, Inc. common stock.
• As of March 31, 2026, Invus Public Equities directly held 366,143 shares, representing 2.1% of the outstanding common stock.
• Avicenna Life Sci Master Fund LP directly held 60,998 shares, also representing 2.1% of the outstanding common stock.
• Raymond Debbane, through his control of various entities, is deemed to beneficially own a total of 427,141 shares, representing 2.5% of the outstanding common stock.
• The total outstanding shares of Tenax Therapeutics, Inc. common stock as of March 6, 2026, were 17,197,613.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant investor interest from established entities, but does not provide operational or financial performance updates.

Positives

• Significant investment by Invus Group entities indicates confidence in Tenax Therapeutics' potential.
• The aggregate beneficial ownership by Raymond Debbane and his associated entities totals 2.5% of the outstanding shares, demonstrating a notable stake.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance from the company itself. The reporting persons certify that the securities were not acquired or held for the purpose of influencing control.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing indicates a significant investment by Invus Group entities in Tenax Therapeutics, a biotechnology company. Such filings often precede or coincide with strategic shifts or increased investor interest in the sector.

Stakeholder Impact

• Shareholders: The increased stake by Invus Group entities may signal potential for future strategic involvement or influence, which could impact share value.
• Management: The filing confirms significant external investment, which may lead to increased scrutiny or engagement from these investors.

Key Dates

Recommendation

The filing indicates a substantial investment by Invus Group entities, suggesting a positive outlook from these investors. However, as this is a beneficial ownership disclosure and not a performance report, it does not provide sufficient information for a strong buy or sell recommendation. A 'hold' is appropriate pending further company-specific news or financial disclosures.

Keywords

Tenax Therapeutics, Schedule 13G, Invus Public Equities, Beneficial Ownership, Common Stock, SEC Filing, Investment